Pataday Twice Daily Relief®
olopatadine 0.1% · ophthalmic solution
Allergy
Approved uses
Itchy and red eyes due to pollen, ragweed, grass, animal hair and dander
1 drop in each affected eye BID, 6 to 8 hours apart
Itch and redness relief begins within 27 minutes and lasts at least 8 hours.
OFF-LABELNot in the FDA label for this product
Contact lens induced papillary conjunctivitis
BID for 8 weeks, with lens wear stopped for the first 4 weeks, as dosed in the trial
RCT · n=85 · no placebo arm
Randomized, double-masked three arm trial in 85 soft lens wearers (170 eyes) with mild to moderate papillary conjunctivitis comparing this concentration, fluorometholone 0.1%, and both: reductions in redness, itching and tearing and the gain in lens tolerance were comparable across arms, olopatadine beat fluorometholone for redness at 8 weeks (P=0.01), and IOP rose significantly with fluorometholone (P=0.003). No placebo arm, and the authors ranked the combination first, olopatadine alone second, fluorometholone alone third. The report gives frequency and duration but not the number of drops per dose.
Vernal keratoconjunctivitis
BID for 8 weeks, as dosed in the trial
Open-label comparative · n=50
Open-label comparative study, randomized per the authors, in 50 children aged 5 to 15 against bepotastine besilate 1.5% BID: both arms reduced signs and symptoms and were equally effective on itching, bepotastine gave quicker relief of watering, discomfort and hyperemia while olopatadine improved papillary hypertrophy faster, and the authors state the between-drug difference was not statistically significant. No placebo arm, single center, and PubMed indexes it as a journal article rather than a randomized controlled trial. The report gives frequency and duration but not the number of drops per dose.
Contraindications
- Do not use if solution changes color or becomes cloudy
- Do not use if you are sensitive to any ingredient in this product
- Do not use to treat contact lens related irritation
Ophthalmic solution, 5 mL bottle, 0.1% (1 mg/mL)
Dual acting topical antiallergic: selective histamine H1 antagonist and conjunctival mast cell stabilizer, so it both blocks histamine already released and limits further mediator release. In a human conjunctival mast cell comparison it inhibited histamine release in a concentration dependent fashion and bound the H1 receptor (Ki 36 nM), while cromolyn and pemirolast produced no significant inhibition.
Warnings & Precautions
- For external use only: Only for use in the eye.
- Contamination: Do not touch tip of container to any surface to avoid contamination.
- When using this product: Remove contact lenses before use, wait at least 10 minutes before reinserting contact lenses after use, and do not wear a contact lens if your eye is red.
- Stop use and ask a doctor: Stop use and ask a doctor if you experience eye pain, changes in vision, increased redness of the eye, or itching that worsens or lasts for more than 72 hours.
- Keep out of reach of children: If swallowed, get medical help or contact a Poison Control Center right away.
Common Side Effects
Ocular and systemic tolerability: No drug-related ocular or non-ocular adverse events in two placebo-controlled challenge studies of 0.05% and 0.1% (169 subjects combined) or in the 98 subject concentration ranging study, all single drop exposures.
Pregnancy: No data in this OTC label.
Lactation: No data in this OTC label.
Labeled for ages 2 and older.